Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Otonomy Inc (OTIC)

Otonomy Inc (OTIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,953
  • Shares Outstanding, K 30,748
  • Annual Sales, $ 750 K
  • Annual Income, $ -50,370 K
  • 60-Month Beta 2.51
  • Price/Sales 92.04
  • Price/Cash Flow N/A
  • Price/Book 1.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.44
  • Number of Estimates 2
  • High Estimate -0.44
  • Low Estimate -0.45
  • Prior Year -0.41
  • Growth Rate Est. (year over year) -7.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.10 +5.24%
on 10/07/19
2.45 -9.80%
on 10/01/19
+0.05 (+2.31%)
since 09/18/19
3-Month
2.10 +5.24%
on 10/07/19
2.96 -25.34%
on 07/31/19
-0.30 (-11.95%)
since 07/18/19
52-Week
1.50 +47.33%
on 12/27/18
3.15 -29.95%
on 05/08/19
-0.38 (-14.67%)
since 10/18/18

Most Recent Stories

More News
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases,...

AGTC : 3.08 (-0.96%)
OTIC : 2.21 (-0.90%)
Otonomy to Present at the Cantor Global Healthcare Conference

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive...

OTIC : 2.21 (-0.90%)
Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-413,...

OTIC : 2.21 (-0.90%)
Otonomy: 2Q Earnings Snapshot

SAN DIEGO (AP) _ Otonomy Inc. (OTIC) on Thursday reported a loss of $11.7 million in its second quarter.

OTIC : 2.21 (-0.90%)
Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update

-- Current capital funds operations into 2021

OTIC : 2.21 (-0.90%)
Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter...

OTIC : 2.21 (-0.90%)
Otonomy (OTIC) Reports Q1 Loss, Misses Revenue Estimates

Otonomy (OTIC) delivered earnings and revenue surprises of 15.22% and -40.92%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

OTIC : 2.21 (-0.90%)
Otonomy: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Otonomy Inc. (OTIC) on Monday reported a loss of $12 million in its first quarter.

OTIC : 2.21 (-0.90%)
Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update

-- OTIPRIO co-promotion agreement completed with Glenmark Therapeutics

OTIC : 2.21 (-0.90%)
Otonomy, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 6, 2019 / Otonomy, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 6, 2019 at 4:30 PM Eastern Time.

OTIC : 2.21 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.

See More Share

Trade OTIC with:

Business Summary

Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company's product candidates under development includes AuriPro to treat pediatric patients with middle...

See More

Key Turning Points

2nd Resistance Point 2.27
1st Resistance Point 2.24
Last Price 2.21
1st Support Level 2.19
2nd Support Level 2.17

See More

52-Week High 3.15
Fibonacci 61.8% 2.52
Fibonacci 50% 2.33
Last Price 2.21
Fibonacci 38.2% 2.13
52-Week Low 1.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar